2-(2-Methyl-1,3-thiazol-4-yl)-2-oxoacetic acid | 1497119-60-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-Methyl-1,3-thiazol-4-yl)-2-oxoacetic acid
• CAS: 1497119-60-4
• 化学式: C₆H₅NO₃S
• 分子量: 171.18
• InChiKey: MEIHQZPKHPXGDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  95.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
  申请人：CHO Young Lag

  公开号：US20120264727A1

  公开（公告）日：2012-10-18

  The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R 1 , and R 2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

  本发明涉及由化学公式1表示的新型头孢菌素衍生物。其中，X、Y、L、R1和R2与发明描述中定义的相同。本发明还涉及包含由化学公式1表示的新型头孢菌素衍生物、前药、水合物、溶剂化物、异构体或药用可接受盐作为有效成分的药物抗生素组合物。根据本发明，新型头孢菌素衍生物、前药、水合物、溶剂化物、异构体或药用可接受盐作为广谱抗生素耐药、低毒性的有效成分，特别是在革兰氏阴性细菌中，可以具有强大的抗菌活性。
• 3-CARBAMOYL-2-PYRIDONE DERIVATIVES
  申请人：ISHIZUKA Natsuki

  公开号：US20120208813A1

  公开（公告）日：2012-08-16

  The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R 1 , R 2 , R 3 , R 4 , and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

  本发明提供了具有激动大麻素受体的活性的化合物，该受体由公式（I）表示：其中R1、R2、R3、R4和G如本文所定义，其药学上可接受的盐或溶剂，以及制备该化合物为活性成分的药物组合物、治疗特应性皮炎的药剂和抗瘙痒剂，尤其是用于口服和外用的抗瘙痒剂。
• ANTIBACTERIAL COMPOUNDS
  申请人：GLAXO GROUP LIMITED

  公开号：US20140249126A1

  公开（公告）日：2014-09-04

  The present invention relates to cephalosporin antibacterial compounds of Formula (I): or corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.

  本发明涉及式（I）的头孢菌素抗菌化合物：或其相应的药学上可接受的盐，相应的制药组合物，化合物制备和治疗细菌感染的方法，特别是由革兰氏阴性菌引起的感染。
• GUANIDINOBENZOIC ACID COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP2757093A1

  公开（公告）日：2014-07-23

  [Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.

  问题 本发明提供了一种可作为预防和/或治疗肾脏疾病的药物的化合物。 [解决方法］ 本发明人对具有胰蛋白酶抑制作用的化合物进行了广泛的研究，结果发现一种胍基苯甲酸化合物具有胰蛋白酶抑制作用，从而完成了本发明。本发明的胍基苯甲酸化合物可用作预防和/或治疗肾病的制剂，作为替代低蛋白饮食疗法的制剂，还可用作预防和/或治疗胰蛋白酶相关疾病的制剂，例如胰腺炎、胃食管反流病、肝性脑病、流感等。
• Combination Medicaments for Treating Bacterial Infections
  申请人：Desarbre Eric

  公开号：US20100144699A1

  公开（公告）日：2010-06-10

  Use of a monobactam antibiotic of formula (I) wherein the oxyimino group i.e. >C═N—O— has Z-orientation, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a bacterial infection in combination with a carbapenem antibiotic or a pharmaceutically acceptable salt thereof.